FDA gedatolisib fulvestrant approval offers new hope in breast cancer

The FDA approval of gedatolisib in combination with fulvestrant expands treatment choices for adults with HR-positive, HER2-negative breast cancer whose disease has progressed after endocrine therapy. This approval provides a new targeted option that meaningfully improves progression-free survival when added to fulvestrant. It specifically applies to patients without PIK3CA mutations and is supported by robust results from the VIKTORIA-1 trial.

The FDA has approved gedatolisib with fulvestrant, with or without palbociclib, for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer following progression on endocrine therapy. The decision was based on statistically significant and clinically meaningful gains in progression-free survival compared with fulvestrant alone. Gedatolisib is administered intravenously once weekly on a 28-day cycle and is continued until disease progression or unacceptable toxicity.

Key Insights

• Median progression-free survival reached 9.3 months with the triplet combination of gedatolisib, fulvestrant, and palbociclib.
• Gedatolisib plus fulvestrant (without palbociclib) achieved a median progression-free survival of 7.4 months.
• Objective response rates increased to 32% and 28% in the two gedatolisib-containing arms, respectively.
• Median duration of response was 17.5 months and 12.0 months in the triplet and doublet arms.
• Key warnings include stomatitis, skin reactions, hyperglycemia, and embryo-fetal toxicity.

These results demonstrate a meaningful delay in disease progression. Although overall survival data remain immature, this approval adds to the growing momentum of new FDA approvals for HR-positive breast cancer treatments.

Ad

Background

The approval was based on Study 1 of the VIKTORIA-1 trial (NCT05501886), an open-label, randomized study that enrolled 392 adults. Patients were assigned to one of three arms: gedatolisib plus fulvestrant and palbociclib, gedatolisib plus fulvestrant alone, or fulvestrant monotherapy. Treatment continued until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival, assessed by blinded independent central review.

Secondary endpoints included overall survival, objective response rate, and duration of response. The FDA utilized its Real-Time Oncology Review program to expedite the evaluation. This decision aligns with other recent access and reimbursement developments in HR+/HER2- breast cancer, including those seen with ribociclib.

Learn more about the FDA gedatolisib fulvestrant approval in this detailed analysis from the agency.

Implications

The reported hazard ratios of 0.24 and 0.33 indicate a substantial reduction in the risk of progression, which may translate into lower use of later-line therapies. Health economics and outcomes research teams can now establish new cost-effectiveness benchmarks incorporating these data. Safety monitoring requirements for hyperglycemia and stomatitis are likely to influence patient adherence, supportive care needs, and overall treatment costs.

This approval also reflects the pharmaceutical industry’s continued focus on the PI3K pathway, building on the success of both mutant-selective PI3Kα inhibitors and broader agents such as inavolisib.

FAQ

How does this approval affect treatment sequencing?

It introduces an intravenous PI3K/mTOR inhibitor that can meaningfully extend progression-free survival when combined with fulvestrant, offering a new option after endocrine therapy progression.

What monitoring does gedatolisib require?

Patients should be regularly monitored for stomatitis, skin reactions, hyperglycemia, and the potential for embryo-fetal toxicity.

Are overall survival results ready?

No. The overall survival data were immature at the time of analysis, with only 25% of deaths observed.